Management of Severe Hypercholesterolemia

Risk Stratification and Treatment Goals

The American Heart Association recommends initiating high-intensity statin therapy immediately to achieve at least a 50% reduction in LDL-C and target LDL-C <100 mg/dL for patients with severe hypercholesterolemia (≥190 mg/dL) 1
For patients with 0-1 risk factors, the LDL-C goal is <160 mg/dL, but aggressive intervention is required for levels ≥190 mg/dL 2, 3, 4
For patients with 2+ risk factors and 10-year CHD risk <10%, the target LDL-C is <130 mg/dL 5, 6
For patients with 2+ risk factors and 10-year CHD risk 10-20%, the target LDL-C is <130 mg/dL, though <100 mg/dL is reasonable 7
For patients with established CHD, diabetes, or 10-year risk >20%, the target LDL-C is <100 mg/dL (or <70 mg/dL for very high-risk patients) 5, 7

The American College of Cardiology recommends starting with high-intensity statin monotherapy as the foundation of treatment, with atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily as first-line agents 1
Therapeutic lifestyle changes, including reducing saturated fat to <7% of total calories, limiting dietary cholesterol to <200 mg/day, eliminating trans-fatty acids, adding plant stanols/sterols 2 g/day, and increasing soluble fiber to 10-25 g/day, should be implemented immediately alongside statin therapy 2, 3, 4, 7
Engaging in at least 30 minutes of moderate-intensity physical activity most days is also recommended 2, 3

If LDL-C remains ≥100 mg/dL after 4-6 weeks on maximally tolerated statin, adding ezetimibe 10 mg daily is recommended, which provides an additional 15-25% LDL-C reduction 1
For refractory severe hypercholesterolemia despite statin + ezetimibe, adding a PCSK9 inhibitor (evolocumab or alirocumab) is recommended, which provides an additional 50-70% LDL-C reduction 1

Initial reassessment at 4-6 weeks after starting or changing therapy is recommended, with monitoring every 3-6 months initially, then annually if stable 1
Screening for secondary causes, such as thyroid function, liver function tests, and urinalysis to rule out nephrotic syndrome, is also recommended 2, 3